N TRK gene fusions involving either NTRK1, NTRK2 or NTRK3 (encoding the neurotrophin
receptors TRKA, TRKB and TRKC, respectively) are oncogenic drivers of various adult and …

Oncogenes that occur in≤ 5% of non-small-cell lung cancers have been defined as 'rare';
nonetheless, this frequency can correspond to a substantial number of patients diagnosed …

PURPOSE An ASCO provisional clinical opinion offers timely clinical direction to ASCO's
membership following publication or presentation of potentially practice-changing data from …

With the FDA approval of larotrectinib, NTRK fusion assessment has recently become a
standard part of management for patients with locally advanced or metastatic cancers …

The fifth edition of the World Health Organization Classification of Tumors of Soft Tissue and
Bone was published in early 2020. The revisions reflect a consensus among an …

Purpose: Targeted next-generation sequencing of DNA has become more widely used in
the management of patients with lung adenocarcinoma; however, no clear mitogenic driver …

Targeted inhibitors of neurotropic tyrosine kinases are highly effective in selected patients
with gene fusions involving NTRK1, NTRK2, or NTRK3. These fusions are consistently …

Abstract Background NTRK1, NTRK2 and NTRK3 fusions are present in a plethora of
malignancies across different histologies. These fusions represent the most frequent …

The fifth edition of the World Health Organization (WHO) classification of soft tissue and
bone tumours was published in May 2020. This 'Blue Book', which is also available digitally …

The world of molecular profiling has undergone revolutionary changes over the last few
years as knowledge, technology, and even standard clinical practice have evolved. Broad …